Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1851-1862

  Derdeyn, Cynthia A ^a,d   Kilby, J Michael ^b   Miralles, G Diego ^c   Li, Li Fang ^a   Sfakianos, Greg ^b   Saag, Michael S ^b   Hockett, Richard D ^a   Bucy, R Pat ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN SITU HYBRIDIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DNA, VIRAL; DRUG THERAPY, COMBINATION; FREEZING; HIV INFECTIONS; HIV-1; HUMANS; IN SITU HYBRIDIZATION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PROVIRUSES; RNA, VIRAL; T-LYMPHOCYTES; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 0032712237     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315117     Document Type: Article

References (65)

1. 1. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 1991; 164:1051-7.
2. 2. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-8.
3. 3. Tenner-Racz K, Racz P. Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Curr Top Microbiol Immunol 1995;201:141-59.
4. 4. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985-9.
5. 5. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-4.
6. 6. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-9.
7. 7. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998;4:341-5.
8. 8. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54.
9. 9. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
10. 10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
11. 11. Mellors J, Rinaldo C, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
12. 12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
13. 13. Gulick RM, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
14. 14. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
15. 15. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
16. 16. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-7.
17. + T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-73.
18. 18. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711-3.
19. 19. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-1. Science 1987; 238:1575-8.
20. 20. Tong-Starksen SE, Luciw PA, Peterlin BM. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci USA 1987; 84:6845-9.
21. 21. Bohnlein E, Lowenthal JW, Siekevitz M, Ballard DW, Franza BR, Greene WC. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell 1988; 53: 827-36.
22. 22. Tong Starkesen SE, Luciw PA, Peterlin BM. Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J Immunol 1989; 142:702-7.
23. 23. Schmidt A, Hennighausen L, Siebenlist U. Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner. J Virol 1990; 64:4037-41.
24. 24. Skowronski J. Expression of a human immunodeficiency virus type 1 long terminal repeat/simian virus 40 early region fusion gene in transgenic mice. J Virol 1991; 65:754-62.
25. 25. Koken SE, van Wamel JL, Goudsmit J, Berkhout B, Geelen JL. Natural variants of the HIV-1 long terminal repeat: analysis of promoters with duplicated DNA regulatory motifs. Virology 1992; 191:968-72.
26. 26. Lu X, Welsh TM, Peterlin BM. The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat. J Virol 1993; 67:1752-60.
27. 27. Antoni BA, Rabson AB, Kinter A, Bodkin M, Poli G. NF-kappa B dependent and independent pathways of HIV activation in a chronically infected T cell line. Virology 1994; 202:684-94.
28. 28. Jones KA, Peterlin BM. Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994; 63:717-43.
29. 29. Song SK, Hongbo L, Cloyd MW. Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region. Virology 1996; 225:377-86.
30. 30. Hockett RD, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999; 189:1545-54.
31. 31. Karr L, Panoskaltsis-Mortari A, Li J, Devore-Carter D, Weaver CT, Bucy RP. In situ hybridization for cytokine mRNA with digoxigenin labeled riboprobes: sensitivity of detection and double label applications. J Immunol Methods 1995; 182:93-106.
32. 32. Panoskaltsis-Mortari A, Bucy RP. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. Biotechniques 1995; 18: 300-7.
33. 33. Dimitrov DH, Melnick JL, Hollinger FB. Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells. J Clin Microbiol 1990; 28:734-7.
34. 34. Gupta P, Enrico A, Armstrong J, Doerr M, Ho M, Rinaldo C. A semi-quantitative microassay for measurement of relative number of blood mononuclear cells infected with human immunodeficiency virus. AIDS Res Hum Retroviruses 1990; 6:1193-6.
35. 35. Hockett RD, Janowski KM, Bucy RP. Simultaneous quantitation of multiple cytokine mRNAs by RT-PCR utilizing plate based EIA methodology. J Immunol Methods 1995; 187:273-85.
36. 36. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32: 292-300.
37. 37. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible vims reservoir in HIV-1 infection. Science 1991; 254:423-7.
38. 38. Vesanen M, Stevens CE, Taylor PE, Rubinstein P, Saksela K. Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1 infected persons. J Virol 1996; 70:9035-40.
39. 39. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-8.
40. 40. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1 infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-90.
41. 41. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66: 1717-25.
42. 42. Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997; 94:5798-803.
43. 43. Robertson G, Garrick D, Wu W, Kearns M, Martin D, Whitelaw E. Position-dependent variegation of globin transgene expression in mice. Proc Natl Acad Sci USA 1995; 92:5371-5.
44. 44. Graubert TA, Hug BA, Wesselschmidt R, et al. Stochastic, stage-specific mechanisms account for the variegation of a human globin transgene. Nucleic Acids Res 1998; 26:2849-58.
45. 45. Garrick D, Sutherland H, Robertson G, Whitelaw E. Variegated expression of a globin transgene correlates with chromatin accessibility but not methylation status. Nucleic Acids Res 1996; 24:4902-9.
46. 46. Feinstein SC, Ross SR, Yamamoto KR. Chromosomal position effects determine transcriptional potential of integrated mammary tumor virus DNA. J Mol Biol 1982; 156:549-65.
47. 47. Winslow BJ, Pomerantz RJ, Bagasra O, Trono D. HIV-1 latency due to the site of proviral integration. Virology 1993; 196:849-54.
48. 48. Chen BK, Saksela K, Andino R, Baltimore D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 1994; 68:654-60.
49. 49. Verdin E, Paras P, van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12:3249-59.
50. 50. McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci USA 1995; 92:5042-6.
51. 51. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995; 375:148-51.
52. 52. Beeson C, Rabinowitz J, Tate K, et al. Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface. J Exp Med 1996; 184:777-82.
53. 53. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. Kinetic discrimination in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 1401-5.
54. 54. Lyons DS, Lieberman SA, Hampl J, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996; 5:53-61.
55. 55. Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med 1997; 185:219-29.
56. 56. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76:263-74.
57. 57. Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996; 14:259-74.
58. 58. Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science 1998; 281:572-5.
59. 59. Bucy RP, Panoskaltsis-Mortari A, Huang GQ, et al. Heterogeneity of single cell cytokine gene expression in clonal T cell populations. J Exp Med 1994; 180:1251-62.
60. + T cell phenotype development. Proc Natl Acad Sci USA 1995; 92:7565-9.
61. 61. Itoh Y, Germain RN. Single cell analysis reveals regulated hierarchical T cell antigen receptor signaling thresholds and intraclonal heterogeneity for individual cytokine responses of CD4 T cells. J Exp Med 1997; 186: 757-66.
62. 62. Bucy RP, Hockett RD, Derdeyn CA, et al. Decreased lymphadenopathy following antiretroviral therapy in HIV disease suggests first phase CD4 T cell increase is due to redistribution from lymphoid tissues to blood. J Clin Invest 1999; 103:1391-8.
63. 63. Bucy RP. Immune clearance of HIV-1 replication active cells: a model of two patterns of steady state HIV infection. AIDS Res Hum Retroviruses 1999; 15:223-7.
64. + lymphocytes. Science 1999; 283: 857-60.
65. + T cell depletion in simian immunodeficiency virus infected macaques. J Exp Med 1999; 189:991-8.